Ulcerative Colitis
Conditions
Brief summary
The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of Lactobacillus reuteri BGP-014 in mild to moderate active Ulcerative Colitis (UC) patients as an oral administered local treatment in addition to Standard of Care (SoC) treatment.
Interventions
BIOLOGICALBGP-014
Oral capsule containing lyophilised Lactobacillus reuteri
BIOLOGICALPlacebo
Oral capsule
Sponsors
BioGaia Pharma AB
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The subject has given written consent to participate in the study. * Diagnosed previously with UC (\> 6 months earlier) determined by clinical and endoscopic histopathology (pathology showing chronic inflammatory changes). ≥1 documented previous flare-up and with last resolved flare \>3 months away. * Active UC determined by sigmoidoscopy before randomisation of study (baseline) and defined as a total Mayo index score of 4 to 10 points (endoscopic subscore ≥1, rectal bleeding ≥1). * Permitted concomitant SoC medications include: Oral aminosalicylates (5-ASA), with a stable dose (1.6-4.8g/ day) for at least 12 days prior to screening, Visit 1. Steroids (dose ≤15mg at screening, Visit 1) with further tapering of dose in accordance with SoC until steroid tx termination. Immunomodulator, as: 6-Mercaptopurine, Azathioprine, Methotrexate (Stable dose for \> 12 weeks prior to screening, Visit 1). * Females of childbearing potential must use effective contraceptives
Exclusion criteria
1. Involvement in any investigational drug or device study within 30 days prior to this study 2. Known intolerance of 5-ASA or sulphasalazine medications 3. Biologics or FMT treatment less than 12 weeks before screening 4. No 5-ASA or steroid topical treatment is allowed 5. Antibiotic treatment \< 1 month prior the study 6. Unable to maintain stable dose of NSAIDs and PPIs 7. Evidence of on-going extensive colitis 8. Fever, defined as a temperature of \>38.5 °C, at Visit 1 9. Anaemia, Hb value below 100 10. Evidence of on-going toxic megacolon 11. Presence of obstructive diseases of the gastrointestinal system 12. Any clinically significant concomitant disease that might interfere with patient safety 13. Unwilling to withdraw probiotic supplements. Yoghurts without supplemented bacteria are permitted 14. Pregnant 15. Planned abdominal surgery 16. Judged unable by the physician to comprehend information regarding the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency and severity of adverse events | Up to 10 weeks | The primary objective is to evaluate the safety and tolerability of BGP-014. |
Countries
Sweden
Outcome results
None listed